4.29
-0.07 (-1.61%)
| Penutupan Terdahulu | 4.36 |
| Buka | 4.28 |
| Jumlah Dagangan | 1,173,736 |
| Purata Dagangan (3B) | 1,197,539 |
| Modal Pasaran | 298,791,232 |
| Harga / Jualan (P/S) | 4.75 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 1 May 2025 |
| Margin Operasi (TTM) | -200.30% |
| EPS Cair (TTM) | -5.29 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 4,249.60% |
| Nisbah Semasa (MRQ) | 4.20 |
| Aliran Tunai Operasi (OCF TTM) | -266.77 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -203.85 M |
| Pulangan Atas Aset (ROA TTM) | -43.78% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Phathom Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -4.0 |
| Purata | -0.13 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.83% |
| % Dimiliki oleh Institusi | 96.98% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Checkpoint Capital L.P. | 31 Dec 2024 | 2,274,157 |
| Catalys Pacific, Llc | 31 Dec 2024 | 1,167,114 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 28.00 (Needham, 552.68%) | Beli |
| Median | 16.00 (272.96%) | |
| Rendah | 5.00 (Goldman Sachs, 16.55%) | Pegang |
| Purata | 16.25 (278.79%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 4.19 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 02 May 2025 | 5.00 (16.55%) | Pegang | 4.29 |
| 17 Apr 2025 | 10.00 (133.10%) | Pegang | 4.03 | |
| Guggenheim | 02 May 2025 | 12.00 (179.72%) | Beli | 4.29 |
| HC Wainwright & Co. | 02 May 2025 | 20.00 (366.20%) | Beli | 4.29 |
| 07 Mar 2025 | 28.00 (552.68%) | Beli | 5.06 | |
| Needham | 21 Apr 2025 | 28.00 (552.68%) | Beli | 3.90 |
| 09 Apr 2025 | 28.00 (552.68%) | Beli | 4.43 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |